



(51) International Patent Classification:

C07K 14/705 (2006.01) C12N 15/90 (2006.01)
C12N 5/06 (2006.01)

(21) International Application Number:

PCT/US2018/058026

(22) International Filing Date:

29 October 2018 (29.10.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/578,153 27 October 2017 (27.10.2017) US

(71) Applicant: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (US).


(72) Inventors: **ROTH, Theodore Lee**; c/o The Regents of the University of California, 1111 Franklin Street, 12th Floor, Oakland, California 94607 (US). **SHIFRUT, Eric**; c/o The Regents of the University of California, 1111 Franklin Street, 12th Floor, Oakland, California 94607 (US). **MARSON, Alexander**; c/o The Regents of the Uni-

versity of California, 1111 Franklin Street, 12th Floor, Oakland, California 94607 (US). **SAUS, Cristina Puig**; c/o The Regents of the University of California, 1111 Franklin Street, 12th Floor, Oakland, California 94607 (US). **RIBAS, Antoni**; c/o The Regents of the University of California, 1111 Franklin Street, 12th Floor, Oakland, California 94607 (US).

(74) Agent: **FERNANDEZ, Lizette** et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORS



(57) Abstract: Provided herein are methods and compositions for editing the genome of a human T cell. In some embodiments, a heterologous T cell receptor (TCR)- β chain and a heterologous TCR- α chain are inserted into exon 1 of a TCR subunit constant gene in the genome of the T cell.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*